CARISMA Therapeutics (STU:W2J) FCF Yield % : -165.17 (As of Jun. 06, 2024)

View and export this data going back to 2023. Start your Free Trial

What is CARISMA Therapeutics FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, CARISMA Therapeutics's Trailing 12-Month Free Cash Flow is €-73.12 Mil, and Market Cap is €43.91 Mil. Therefore, CARISMA Therapeutics's FCF Yield % for today is -165.17%.

The historical rank and industry rank for CARISMA Therapeutics's FCF Yield % or its related term are showing as below:

STU:W2J' s FCF Yield % Range Over the Past 10 Years
Min: -190.84 Med: -83.42 Max: -7.47
Current: -165.17

During the past 4 years, the highest FCF Yield % of CARISMA Therapeutics was -7.47%. The lowest was -190.84%. And the median was -83.42%.

STU:W2J's FCF Yield % is ranked worse than
90.21% of 1553 companies
in the Biotechnology industry
Industry Median: -14.28 vs STU:W2J: -165.17

CARISMA Therapeutics's FCF Margin % for the quarter that ended in Mar. 2024 was -660.70%.

CARISMA Therapeutics FCF Yield % Historical Data

The historical data trend for CARISMA Therapeutics's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CARISMA Therapeutics FCF Yield % Chart

CARISMA Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

FCF Yield %

-69.87

CARISMA Therapeutics Quarterly Data
	Dec20	Jun21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
FCF Yield %	Get a 7-Day Free Trial							-86.47	-21.54	-47.82	-56.56	-94.67

Competitive Comparison of CARISMA Therapeutics's FCF Yield %

For the Biotechnology subindustry, CARISMA Therapeutics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CARISMA Therapeutics's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CARISMA Therapeutics's FCF Yield % distribution charts can be found below:

* The bar in red indicates where CARISMA Therapeutics's FCF Yield % falls into.

CARISMA Therapeutics FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

CARISMA Therapeutics's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	/	Market Cap
	=	-75.477	/	108.022334
	=	-69.87%

CARISMA Therapeutics's annualized FCF Yield % for the quarter that ended in Mar. 2024 is calculated as

FCF Yield %	=	Free Cash Flow	*	Annualized Factor	/	Market Cap
	=	-20.647	*	4	/	87.23967
	=	-94.67%

CARISMA Therapeutics FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

CARISMA Therapeutics FCF Yield % Related Terms

Thank you for viewing the detailed overview of CARISMA Therapeutics's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

CARISMA Therapeutics (STU:W2J) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CARISMA Therapeutics Inc (STU:W2J) » Definitions » FCF Yield %

Comparable Companies

Traded in Other Exchanges

CARM:USA W2J:Germany

Address

245 First Street, Suite 1800, Cambridge, MA, USA, 02142

Website

https://www.carismatx.com

CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma's proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells.

CARISMA Therapeutics (STU:W2J) Headlines

No Headlines